Truist Financial Corp Has $353,000 Stock Position in Organon & Co. (NYSE:OGN)

Truist Financial Corp lessened its holdings in Organon & Co. (NYSE:OGN) by 9.9% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 17,063 shares of the company’s stock after selling 1,873 shares during the period. Truist Financial Corp’s holdings in Organon & Co. were worth $353,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Mercer Global Advisors Inc. ADV grew its holdings in shares of Organon & Co. by 1.8% during the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 31,086 shares of the company’s stock worth $674,000 after purchasing an additional 546 shares in the last quarter. Ballentine Partners LLC increased its holdings in Organon & Co. by 3.0% in the second quarter. Ballentine Partners LLC now owns 19,105 shares of the company’s stock worth $395,000 after purchasing an additional 552 shares in the last quarter. Atomi Financial Group Inc. increased its holdings in Organon & Co. by 1.8% in the first quarter. Atomi Financial Group Inc. now owns 32,858 shares of the company’s stock worth $618,000 after purchasing an additional 593 shares in the last quarter. Bill Few Associates Inc. increased its holdings in Organon & Co. by 5.4% in the second quarter. Bill Few Associates Inc. now owns 12,218 shares of the company’s stock worth $253,000 after purchasing an additional 621 shares in the last quarter. Finally, GAMMA Investing LLC grew its stake in Organon & Co. by 19.2% in the second quarter. GAMMA Investing LLC now owns 4,036 shares of the company’s stock valued at $84,000 after acquiring an additional 649 shares during the period. Institutional investors own 77.43% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have commented on OGN shares. Evercore ISI raised Organon & Co. to a “strong-buy” rating in a research note on Wednesday, September 18th. JPMorgan Chase & Co. lowered Organon & Co. from a “neutral” rating to an “underweight” rating and lifted their price target for the stock from $18.00 to $20.00 in a report on Friday, September 6th.

Organon & Co. Price Performance

OGN opened at $17.64 on Friday. The stock has a 50-day moving average price of $20.03 and a 200-day moving average price of $20.13. Organon & Co. has a 12-month low of $10.84 and a 12-month high of $23.10. The company has a current ratio of 1.64, a quick ratio of 1.17 and a debt-to-equity ratio of 60.05. The stock has a market capitalization of $4.54 billion, a P/E ratio of 4.31, a PEG ratio of 0.79 and a beta of 0.84.

Organon & Co. (NYSE:OGN) last released its quarterly earnings results on Tuesday, August 6th. The company reported $1.12 EPS for the quarter, beating analysts’ consensus estimates of $1.08 by $0.04. The business had revenue of $1.61 billion during the quarter, compared to analyst estimates of $1.61 billion. Organon & Co. had a negative return on equity of 840.29% and a net margin of 15.76%. Organon & Co.’s quarterly revenue was down .1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.31 EPS. Equities analysts predict that Organon & Co. will post 4.15 earnings per share for the current fiscal year.

Organon & Co. Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, September 12th. Shareholders of record on Friday, August 16th were paid a dividend of $0.28 per share. The ex-dividend date of this dividend was Friday, August 16th. This represents a $1.12 annualized dividend and a yield of 6.35%. Organon & Co.’s dividend payout ratio is 27.38%.

About Organon & Co.

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.